Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Publisher's site:
http://dx.doi.org/10.15585/mmwr.mm6824a4
Description:
CDC is expecting a 3-10 month nationwide shortage of Aplisol, a product of Par Pharmaceuticals, and one of two purified-protein derivative (PPD) tuberculin antigens licensed by the Food and Drug Administration (FDA) for use in performing tuberculin skin tests. This time frame is the manufacturer's current estimate and is subject to change. The manufacturer notified CDC that they anticipate an interruption of supply of Aplisol 5 mL (50 multidose vials) beginning in June 2019, followed by an interruption of the supply of Aplisol 1 mL (10 multidose vials) in November 2019. The expected shortage of Aplisol 1 mL could occur before November 2019 if demand increases before then. Information on the status of this supply interruption will be updated at FDA's Center for Biologics Evaluation and Research-Regulated Products: Current Shortages website (https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages). This report includes CDC recommendations for mitigating a reduction in tuberculosis (TB) testing capability resulting from the anticipated Aplisol shortage (1).
Subject:
[+]
Antigens, Bacterial
Full Report
Humans
Practice Guidelines As Topic
Public Health Practice
Tuberculin Test
Tuberculosis

Source:
MMWR Morb Mortal Wkly Rep. 68(24):552-553
Pubmed ID:
31220054
Pubmed Central ID:
PMC6586373
Document Type:
Journal Article
Name as Subject:
Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.)
Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.) Less -
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:0075b00854ba9092e5199e4e105e4cbb50e2968b112a61c5abe2f2d067ace551
File Type:

Supporting Files

• mm6824a4.nxml

  xml

More +